Gilead Sciences Inc. (GILD) financial statements: income statement, balance sheet and cash flow
Gilead Sciences Inc.'s income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Gilead Sciences Inc. reported revenue of $29.4B (+2.4% year on year) and net income of $8.5B (+1672.9% year on year).
Income statement
Gilead Sciences Inc. income statement, fiscal years
Line item
Dec 31, 2025 · FY
Dec 31, 2024 · FY
Dec 31, 2023 · FY
Dec 31, 2022 · FY
Total revenues
$29.4B
$28.8B
$27.1B
$27.3B
Cost of goods sold
$6.2B
$6.3B
$6.5B
$5.7B
Research and development expenses
$5.8B
$5.9B
$5.7B
$5.0B
Acquired in-process research and development expenses
$1.0B
$4.7B
$1.2B
$944.0M
In-process research and development impairments
$590.0M
$4.2B
$50.0M
$2.7B
Selling, general and administrative expenses
$5.8B
$6.1B
$6.1B
$5.7B
Total costs and expenses
$19.4B
$27.1B
$19.5B
$20.0B
Operating income
$10.0B
$1.7B
$7.6B
$7.3B
Interest expense
$1.0B
$977.0M
($944.0M)
($935.0M)
Other (income) expense, net
($798.0M)
($6.0M)
$198.0M
($581.0M)
Income before income taxes
$9.8B
$690.0M
$6.9B
$5.8B
Income tax (benefit) expense
$1.3B
$211.0M
($1.2B)
($1.2B)
Net income
$8.5B
$480.0M
$5.6B
$4.6B
Net loss attributable to noncontrolling interest
$0
$0
$52.0M
$26.0M
Net income attributable to Gilead
$8.5B
$480.0M
$5.7B
$4.6B
Basic earnings per share attributable to Gilead (in dollars per share)
$6.84
$0.38
$4.54
$3.66
Diluted earnings per share attributable to Gilead (in dollars per share)
$6.78
$0.38
$4.50
$3.64
Shares used in basic earnings per share attributable to Gilead calculation (in shares)
$1244000000.00
$1247000000.00
$1248000000.00
$1255000000.00
Shares used in diluted earnings per share attributable to Gilead calculation (in shares)
$1255000000.00
$1255000000.00
$1258000000.00
$1262000000.00
Gilead Sciences Inc. income statement, quarters
Line item
Jun 30, 2026 · Q2
Mar 31, 2026 · Q1
Sep 30, 2025 · Q3
Jun 30, 2025 · Q2
Total revenues
$7.8B
$7.0B
$7.8B
$7.1B
Cost of goods sold
$1.6B
$1.4B
$1.6B
$1.5B
Research and development expenses
$1.8B
$1.4B
$1.3B
$1.5B
Acquired in-process research and development expenses
$11.2B
$107.0M
$170.0M
$61.0M
In-process research and development impairments
$1.8B
—
$0
$190.0M
Selling, general and administrative expenses
$1.9B
$1.5B
$1.4B
$1.4B
Total costs and expenses
$18.2B
$4.4B
$4.4B
$4.6B
Operating (loss) income
($10.4B)
$2.6B
$3.3B
$2.5B
Interest expense
$247.0M
$240.0M
$256.0M
$254.0M
Other (income) expense, net
($387.0M)
($235.0M)
($569.0M)
($208.0M)
(Loss) income before income taxes
($10.3B)
$2.6B
$3.6B
$2.4B
Income tax expense
$242.0M
$559.0M
$589.0M
$468.0M
Net (loss) income
($10.5B)
$2.0B
$3.1B
$2.0B
Basic (loss) earnings per share (in dollars per share)
-$8.45
$1.63
$2.46
$1.57
Diluted (loss) earnings per share (in dollars per share)
-$8.45
$1.61
$2.43
$1.56
Shares used in basic (loss) earnings per share calculation (in shares)
$1243000000.00
$1242000000.00
$1243000000.00
$1245000000.00
Shares used in diluted (loss) earnings per share calculation (in shares)
$1243000000.00
$1254000000.00
$1254000000.00
$1255000000.00
Balance sheet
Gilead Sciences Inc. balance sheet, fiscal years
Line item
Dec 31, 2025 · FY
Dec 31, 2024 · FY
Dec 31, 2023 · FY
Dec 31, 2022 · FY
Cash and cash equivalents
$7.6B
$10.0B
$6.1B
$5.4B
Short-term marketable debt securities
$68.0M
$0
$1.2B
$973.0M
Accounts receivable, net
$4.9B
$4.4B
$4.7B
$4.8B
Inventories
$1.8B
$1.7B
$1.8B
$1.5B
Prepaid and other current assets
$4.0B
$3.1B
$2.4B
$1.8B
Total current assets
$18.3B
$19.2B
$16.1B
$14.4B
Property, plant and equipment, net
$5.6B
$5.4B
$5.3B
$5.5B
Long-term marketable debt securities
$3.0B
$0
$1.2B
$1.2B
Intangible assets, net
$17.0B
$19.9B
$26.5B
$28.9B
Goodwill
$8.3B
$8.3B
$8.3B
$8.3B
Deferred tax assets
$2.0B
—
—
—
Other long-term assets
$4.8B
$6.1B
$4.8B
$4.8B
Total assets
$59.0B
$59.0B
$62.1B
$63.2B
Accounts payable
$715.0M
$833.0M
$550.0M
$905.0M
Accrued rebates
$4.3B
$3.9B
$3.8B
$3.5B
Current portion of long-term debt, net
$2.8B
$1.8B
$1.8B
$2.3B
Other current liabilities
$4.0B
$5.5B
$5.1B
$4.6B
Total current liabilities
$11.8B
$12.0B
$11.3B
$11.2B
Long-term debt, net
$22.1B
$24.9B
$23.2B
$23.0B
Long-term income taxes payable
$896.0M
$830.0M
$2.0B
$3.9B
Deferred tax liabilities
$402.0M
$724.0M
$1.6B
$2.7B
Other long-term liabilities
$1.2B
$1.3B
$1.3B
$1.2B
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding
$0.00
$0.00
$0.00
$0.00
Common stock, par value $0.001 per share; 5,600 authorized; 1,241 and 1,246 shares issued and outstanding, respectively
$1000000.00
$1000000.00
$1000000.00
$1000000.00
Additional paid-in capital
$8.9B
$7.7B
$6.5B
$5.5B
Accumulated other comprehensive income
$39.0M
$132.0M
$28.0M
$2.0M
Retained earnings
$13.7B
$11.5B
$16.3B
$15.7B
Total Gilead stockholders’ equity
$22.7B
$19.3B
$22.8B
$21.2B
Noncontrolling interest
($84.0M)
($84.0M)
($84.0M)
($31.0M)
Total stockholders’ equity
$22.6B
$19.2B
$22.7B
$21.2B
Total liabilities and stockholders’ equity
$59.0B
$59.0B
$62.1B
$63.2B
Gilead Sciences Inc. balance sheet, quarters
Line item
Jun 30, 2026
Mar 31, 2026
Sep 30, 2025
Jun 30, 2025
Cash and cash equivalents
$3.2B
$7.6B
$7.3B
$5.1B
Short-term marketable debt securities
$0
$15.0M
$19.0M
$69.0M
Accounts receivable, net
$5.1B
$4.7B
$5.1B
$4.8B
Inventories
$2.0B
$1.9B
$1.8B
$1.8B
Prepaid and other current assets
$3.8B
$4.3B
$3.6B
$2.9B
Total current assets
$13.9B
$18.6B
$17.9B
$14.7B
Property, plant and equipment, net
$5.8B
$5.6B
$5.5B
$5.5B
Long-term marketable debt securities
$0
$983.0M
$2.0B
$1.9B
Intangible assets, net
$14.0B
$16.4B
$18.0B
$18.6B
Goodwill
$8.3B
$8.3B
$8.3B
$8.3B
Deferred tax assets
$2.5B
$1.8B
$2.0B
$2.7B
Other long-term assets
$4.8B
$4.6B
$4.9B
$4.0B
Total assets
$49.4B
$56.3B
$58.5B
$55.7B
Accounts payable
$674.0M
$645.0M
$808.0M
$582.0M
Accrued rebates
$4.2B
$4.1B
$4.9B
$4.2B
Current portion of long-term debt, net
$2.4B
$1.3B
$2.8B
$2.8B
Other current liabilities
$3.7B
$3.4B
$3.8B
$3.6B
Total current liabilities
$11.0B
$9.5B
$12.3B
$11.2B
Long-term debt, net
$23.8B
$20.9B
$22.1B
$22.1B
Long-term income taxes payable
$943.0M
$918.0M
$866.0M
$859.0M
Deferred tax liabilities
$333.0M
$392.0M
$597.0M
$652.0M
Other long-term liabilities
$1.5B
$1.2B
$1.2B
$1.3B
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding
$0.00
$0.00
$0.00
$0.00
Common stock, par value $0.001 per share; 5,600 shares authorized; 1,241 shares issued and outstanding
$1000000.00
$1000000.00
$1000000.00
$1000000.00
Additional paid-in capital
$9.5B
$9.3B
$8.7B
$8.4B
Accumulated other comprehensive income
$95.0M
$78.0M
$36.0M
($18.0M)
Retained earnings
$2.2B
$14.1B
$12.8B
$11.3B
Total Gilead stockholders’ equity
$11.8B
$23.5B
$21.5B
$19.7B
Noncontrolling interest
($84.0M)
($84.0M)
($84.0M)
($84.0M)
Total stockholders’ equity
$11.7B
$23.4B
$21.5B
$19.6B
Total liabilities and stockholders’ equity
$49.4B
$56.3B
$58.5B
$55.7B
Cash flow statement
Gilead Sciences Inc. cash flow statement, fiscal years
Line item
Dec 31, 2025 · FY
Dec 31, 2024 · FY
Dec 31, 2023 · FY
Dec 31, 2022 · FY
Net income
$8.5B
$480.0M
$5.6B
$4.6B
Depreciation expense
$370.0M
$381.0M
$354.0M
$323.0M
Amortization expense
$2.4B
$2.4B
$2.3B
$1.8B
Stock-based compensation expense
$894.0M
$835.0M
$766.0M
$637.0M
Deferred income taxes
$160.0M
($1.8B)
($962.0M)
($1.6B)
Net (gain) loss from equity securities
($451.0M)
$274.0M
$167.0M
$657.0M
Acquired in-process research and development expenses
$1.0B
$4.7B
$1.2B
$944.0M
In-process research and development impairments
$590.0M
$4.2B
$50.0M
$2.7B
Other, net
$480.0M
$353.0M
$826.0M
$780.0M
Accounts receivable, net
($367.0M)
$139.0M
$157.0M
($406.0M)
Inventories
($1.0B)
($426.0M)
($842.0M)
($310.0M)
Prepaid expenses and other
($311.0M)
($259.0M)
$39.0M
$70.0M
Accounts payable
($132.0M)
$290.0M
($347.0M)
$226.0M
Income tax assets and liabilities, net
($2.1B)
($732.0M)
($1.8B)
—
Accrued and other liabilities
$6.0M
$108.0M
$458.0M
($775.0M)
Net cash provided by operating activities
$10.0B
$10.8B
$8.0B
$9.1B
Purchases of marketable debt securities
($3.9B)
($244.0M)
($1.9B)
($1.8B)
Proceeds from sales of marketable debt securities
$854.0M
$2.3B
$510.0M
$412.0M
Proceeds from maturities of marketable debt securities
$55.0M
$327.0M
$1.3B
$1.6B
Acquisitions, including in-process research and development, net of cash acquired
($1.1B)
($4.8B)
($1.2B)
($1.8B)
Purchases of equity securities
($133.0M)
($492.0M)
($442.0M)
($172.0M)
Purchases of property, plant and equipment
($563.0M)
($523.0M)
($585.0M)
($728.0M)
Other investing activities, net
$2.0M
$58.0M
($1.0M)
($1.0M)
Net cash used in investing activities
($4.8B)
($3.4B)
($2.3B)
($2.5B)
Proceeds from debt financing, net of issuance costs
$0
$3.5B
$2.0B
$0
Proceeds from issuances of common stock
$408.0M
$422.0M
$232.0M
$309.0M
Repurchases of common stock under repurchase programs
($1.9B)
($1.1B)
($1.0B)
($1.4B)
Repayments of debt and other obligations
($1.8B)
($2.0B)
($2.3B)
($1.5B)
Payments of dividends
($4.0B)
($3.9B)
($3.8B)
($3.7B)
Other financing activities, net
($440.0M)
($281.0M)
($279.0M)
($173.0M)
Net cash used in financing activities
($7.7B)
($3.4B)
($5.1B)
($6.5B)
Effect of exchange rate changes on cash and cash equivalents
$92.0M
($40.0M)
$57.0M
($63.0M)
Net change in cash and cash equivalents
($2.4B)
$3.9B
$673.0M
$74.0M
Cash and cash equivalents at beginning of period
$10.0B
$6.1B
$5.4B
$5.3B
Cash and cash equivalents at end of period
$7.6B
$10.0B
$6.1B
$5.4B
Gilead Sciences Inc. cash flow statement, quarters
Line item
Jun 30, 2026 · YTD
Mar 31, 2026 · Q1
Sep 30, 2025 · YTD
Jun 30, 2025 · YTD
Net (loss) income
($8.5B)
$2.0B
—
—
Depreciation expense
$191.0M
$93.0M
$280.0M
$190.0M
Amortization expense
$1.2B
$596.0M
$1.8B
$1.2B
Stock-based compensation expense
$449.0M
$218.0M
$664.0M
$434.0M
Deferred income taxes
($408.0M)
$179.0M
$282.0M
($377.0M)
Net (gain) loss from equity securities
($485.0M)
($142.0M)
($198.0M)
$284.0M
Acquired in-process research and development expenses
$12.2B
$107.0M
$485.0M
$315.0M
In-process research and development impairments
$1.8B
—
$190.0M
$190.0M
Other, net
$423.0M
$183.0M
$213.0M
$124.0M
Accounts receivable, net
($199.0M)
$134.0M
($546.0M)
($213.0M)
Inventories
($197.0M)
($52.0M)
($913.0M)
($398.0M)
Prepaid expenses and other
($8.0M)
$5.0M
($275.0M)
$93.0M
Accounts payable
($49.0M)
($67.0M)
($37.0M)
($267.0M)
Income tax assets and liabilities, net
$142.0M
($29.0M)
($2.0B)
($1.9B)
Accrued and other liabilities
($364.0M)
($702.0M)
$401.0M
($410.0M)
Net cash provided by operating activities
$6.1B
$2.5B
$6.7B
$2.6B
Purchases of marketable debt securities
($551.0M)
($525.0M)
($2.6B)
($2.3B)
Proceeds from sales of marketable debt securities
$3.5B
$2.5B
$514.0M
$295.0M
Proceeds from maturities of marketable debt securities
$37.0M
$36.0M
$32.0M
$15.0M
Acquisitions, including in-process research and development, net of cash acquired
($11.3B)
($109.0M)
($461.0M)
($294.0M)
Purchases of equity securities
($35.0M)
($19.0M)
($119.0M)
($37.0M)
Purchases of property, plant and equipment
($257.0M)
($117.0M)
($358.0M)
($211.0M)
Other investing activities, net
$3.0M
($17.0M)
($9.0M)
($13.0M)
Net cash used in investing activities
($8.6B)
$1.8B
($3.0B)
($2.5B)
Proceeds from debt financing, net of issuance costs
$4.1B
—
—
—
Proceeds from issuances of common stock
$175.0M
$166.0M
$376.0M
$279.0M
Repurchases of common stock under repurchase programs
($774.0M)
($419.0M)
($1.7B)
($1.3B)
Repayments of debt and other obligations
($2.8B)
($2.8B)
($1.8B)
($1.8B)
Payments of dividends
($2.1B)
($1.0B)
($3.0B)
($2.0B)
Other financing activities, net
($529.0M)
($179.0M)
($377.0M)
($240.0M)
Net cash used in financing activities
($1.9B)
($4.2B)
($6.5B)
($5.0B)
Effect of exchange rate changes on cash and cash equivalents